Table 2.
Summary OR and 95% CI for the GALNT1 SNP rs17647532 and risk of invasive epithelial ovarian cancer among non-Hispanic Caucasians
| Site | N | Case/control |
MAF* | PHWE† | Additive model,‡ OR (95% CI) | Recessive model,‡ OR (95% CI) | ||
|---|---|---|---|---|---|---|---|---|
| CC | CT | TT | ||||||
| Discovery | ||||||||
| MAY | 846 | 1/12 | 70/71 | 314/378 | 0.10 | 0.0003 | 0.88 (0.64–1.21) | 0.14 (0.02–1.14) |
| NCO-1 (Duke) | 922 | 0/8 | 80/91 | 364/379 | 0.10 | 0.35 | 0.78 (0.57–1.06) | NA |
| Replication | ||||||||
| AUS | 1,994 | 12/16 | 185/207 | 733/841 | 0.11 | 0.44 | 1.00 (0.82–1.21) | 0.84 (0.4–1.8) |
| DOV | 1,237 | 7/4 | 109/133 | 504/480 | 0.11 | 0.16 | 0.85 (0.66–1.11) | 1.75 (0.51–6.03) |
| GER | 679 | 2/4 | 43/75 | 206/349 | 0.10 | 1.00 | 0.96 (0.66–1.39) | 0.83 (0.15–4.58) |
| HAW | 248 | 2/0 | 18/39 | 70/119 | 0.12 | 0.13 | 0.97 (0.54–1.74) | NA |
| HOP | 901 | 1/5 | 69/124 | 237/465 | 0.11 | 0.41 | 1.05 (0.76–1.46) | 0.37 (0.04–3.19) |
| MAL | 1,234 | 7/9 | 77/152 | 356/633 | 0.11 | 1.00 | 0.96 (0.73–1.25) | 1.4 (0.51–3.83) |
| NCO-2 | 452 | 4/3 | 46/41 | 200/158 | 0.12 | 0.74 | 0.92 (0.61–1.38) | 1.17 (0.26–5.36) |
| NEC | 2,032 | 11/8 | 97/92 | 380/397 | 0.10 | 0.09 | 1.11 (0.91–1.35) | 1.00 (0.48–2.08) |
| POL | 872 | 2/9 | 47/95 | 226/493 | 0.09 | 0.35 | 0.98 (0.70–1.38) | 0.49 (0.1–2.27) |
| SEA | 2,305 | 19/20 | 196/245 | 877/948 | 0.12 | 0.33 | 0.93 (0.77–1.12) | 1.00 (0.52–1.92) |
| STA | 550 | 3/1 | 76/37 | 290/143 | 0.11 | 0.70 | 1.01 (0.66–1.53) | 1.27 (0.13–12.43) |
| UCI | 822 | 8/2 | 79/83 | 317/333 | 0.10 | 0.29 | 1.13 (0.83–1.54) | 3.92 (0.82–18.65) |
| UKO | 1,031 | 6/8 | 81/100 | 380/456 | 0.10 | 0.36 | 0.96 (0.71–1.31) | 0.71 (0.21–2.43) |
| USC | 985 | 14/15 | 192/184 | 776/851 | 0.11 | 0.18 | 1.12 (0.86–1.47) | 1.41 (0.56–3.55) |
| Overall§ | 15,342 | 98/104 | 1,315/1,607 | 5,552/6,666 | 0.11 | 0.76 | 0.99 (0.92–1.07) | 1.12 (0.85–1.49) |
| Cumulative summary|| | 17,108 | 99/124 | 1,465/1,768 | 6,230/7,422 | 0.11 | 0.11 | 0.98 (0.91–1.05) | 0.94 (0.72–1.23) |
NOTE: The discovery set includes two sites (MAY and NCO-1) and the replication set includes 14 OCAC sites (AUS, DOV, GER, HAW, HOP, MAL, NCO-2, NEC, POL, SEA, STA, UCI, UKO, and USC). The study site nomenclature is described in Materials and Methods.
Abbreviation: MAF, minor allele frequency.
*
MAF estimated among controls.
†
P value for testing departure from HWE among controls.
‡
ORs and 95% CIs in models adjusted for age groups.
§
Summary results across all 14 OCAC replication sites.
||
Cumulative summary including previously published data from Mayo and Duke (NCO-1).